Dupixent Face Rash: Causes and Management

Dupixent (dupilumab) face rash is a recognized side effect in which patients being treated for atopic dermatitis develop new or worsening redness, irritation, and sometimes flaking on the face and neck, even as their eczema elsewhere improves. Pooled data from phase 3 trials put the incidence at roughly 1% of dupilumab-treated patients, though real-world reports suggest the true rate may be higher because milder cases often go unrecognized or unreported. The paradox of developing a new facial problem while a skin disease is getting better is understandably frustrating, and the causes turn out to involve a surprisingly complex mix of shifting immune responses and changes to the skin’s microbial residents.

What the Rash Looks Like

The most common presentation is a diffuse, sometimes patchy redness across the cheeks, around the eyes, or extending down the neck. Most patients also report itching, though the quality of the itch often feels different from the deep, intense itch of active atopic dermatitis. In a study of 21 patients with dupilumab-associated facial redness, erythema and pruritus were the dominant features, and they looked distinct from the patients’ typical moderate-to-severe eczema flares.¹ Some people develop a fine, dry scale or a slightly bumpy texture that can resemble rosacea. Less commonly, the rash takes on an acneiform pattern with small pustules.

Skin biopsies from affected patients show widened small blood vessels (which explains the visible redness) and a mixed inflammatory infiltrate around those vessels. Researchers have noted that the biopsy pattern can look surprisingly similar to psoriasis, with thickened epidermis and elongated rete ridges, but without the spongiosis (fluid between skin cells) that typically characterizes eczema.² That psoriasiform pattern is a clue that the inflammation driving the rash is mechanistically different from regular atopic dermatitis, not just a leftover flare that dupilumab failed to suppress.

How Common It Really Is

In a pooled analysis of phase 3 trials involving over 2,600 dupilumab-treated patients and about 1,350 on placebo, facial rash events occurred in 1.0% of the dupilumab group compared with 0.7% on placebo. Most cases were mild to moderate, and none led to treatment discontinuation.³ Those numbers sound reassuringly small, but clinical trials tend to undercount side effects that develop gradually or that patients attribute to their underlying eczema. Real-world case series and retrospective studies consistently describe the phenomenon at higher rates, partly because clinicians now know to look for it. The gap between trial data and clinic experience is worth knowing about: if your dermatologist has seen plenty of patients with this rash, that is not at odds with the trial statistics.

One descriptive study found that among patients who had no active facial dermatitis before starting dupilumab, about a quarter developed new-onset facial erythema after beginning treatment.⁴ That figure comes from a small cohort and should not be read as a population-wide rate, but it highlights the fact that this rash can appear even in people whose face was clear before dupilumab.

Why Dupilumab Triggers Facial Redness

No single mechanism fully explains the rash, and the honest answer from the research community is that it is probably multifactorial. Three leading theories have the most evidence behind them, and they are not mutually exclusive.

A Shift in the Immune Balance

Dupilumab works by blocking two signaling molecules, interleukin-4 and interleukin-13, that drive the allergic (Th2) arm of the immune system. When you suppress that arm hard enough, the immune system does not simply quiet down everywhere. Other arms can become relatively more active. Research on lesional skin from patients with dupilumab-associated head and neck dermatitis has found a pronounced increase in IL-22-driven inflammation, with expanded populations of T cells producing IL-22 and upregulated IL-22 receptors on skin cells.⁵ IL-22 is a cytokine linked to keratinocyte activation and skin thickening, a different flavor of inflammation from the one dupilumab was designed to calm.

At the same time, blocking IL-4 appears to tip the balance toward Th1 and Th17 immune responses, which are the pathways involved in conditions like psoriasis and certain fungal-driven skin reactions.⁶ The face and neck may be disproportionately affected because those areas have the highest density of sebaceous glands and a unique microbial ecology that responds strongly to these immune shifts.

Malassezia Yeast Overgrowth

The skin’s fungal residents, particularly a yeast called Malassezia, are a major suspect. Malassezia species live on everyone’s skin, concentrated in oily areas like the face, scalp, and upper chest. In people with atopic dermatitis, the immune environment normally keeps Malassezia somewhat in check, even as it also fosters an overabundance of Staphylococcus aureus bacteria. When dupilumab suppresses the Th2 response and S. aureus populations drop, the microbial balance can shift in favor of Malassezia.⁷

Malassezia that penetrate a compromised skin barrier can trigger local inflammation by activating skin cells and prompting the immune system to produce yeast-specific antibodies.⁸ This helps explain why some patients respond well to antifungal treatments, a pattern that would make no sense if the rash were purely an immune rebound phenomenon.

Demodex Mite Proliferation

A third contributor involves Demodex mites, microscopic organisms that live in hair follicles. In adolescents and adults on dupilumab, case reports have described acute acneiform eruptions in which skin scrapings revealed heavy Demodex colonization. Researchers theorize that dupilumab’s immunomodulation allows baseline Demodex populations to expand unchecked, particularly in patients whose facial immune surveillance was already altered by their atopic dermatitis.⁹ This mite-driven form of facial rash tends to look more like rosacea or folliculitis, with small bumps or pustules rather than the flat redness seen in other presentations.¹⁰

Does Prior Topical Steroid Use Matter?

There is a persistent question about whether prior use of topical corticosteroids on the face sets the stage for dupilumab-associated redness. In one descriptive study, a large majority of patients who developed facial erythema on dupilumab, whether as a new problem or as worsening of existing redness, had a history of using topical steroids on their face. Among patients with exacerbated facial redness, 86% had previously used facial steroids, and among those with completely new-onset redness, 67% had a similar history.⁴ The clinical appearance was similar in both groups.

This association has led some dermatologists to wonder whether the rash overlaps with topical steroid withdrawal, a condition in which the skin rebounds with redness and burning after long-term steroid use is reduced. Because many people starting dupilumab are simultaneously cutting back on their topical steroids (their eczema is improving, so they stop applying them), it can be genuinely difficult to separate the two phenomena. The leading view is that topical steroid history is a risk factor that increases susceptibility, but it is not the sole cause in most cases.

Who Is More Likely to Develop It

Predicting which patients will develop dupilumab-associated facial redness remains a challenge. A machine-learning study that analyzed blood markers and clinical features identified eight factors most strongly associated with facial erythema severity: age, sex, lactate dehydrogenase levels, total immunoglobulin E, eosinophil count, white blood cell count, and specific allergies to alder and cedar pollen.¹¹ The model was able to distinguish patients whose facial redness resolved early from those who had persistent erythema with about 89% accuracy, suggesting the condition has reproducible biological predictors. Practically, this means your blood work and allergy profile might eventually help your dermatologist estimate your risk, though the tool is not yet part of routine clinical practice.

Getting the Right Diagnosis

Not every rash that appears on the face during dupilumab treatment is the “dupilumab face rash.” Allergic contact dermatitis is a common mimicker. It turns out that dupilumab does not suppress the type of immune reaction responsible for contact allergies. In a study of patients who were patch tested while actively taking dupilumab, every single one still showed at least one positive reaction, confirming that dupilumab does not mask contact allergy results.¹² So if your face breaks out in a pattern that follows where you apply a particular skincare product or sunscreen, the culprit may be a contact allergen that was previously hidden by the widespread eczema, now unmasked as the eczema clears.

Your dermatologist might also consider seborrheic dermatitis (which overlaps with the Malassezia-driven mechanism), rosacea, perioral dermatitis, or, in some cases, actual eczema that simply persists on the face even as the body clears. Each of these has somewhat different implications for treatment. A skin scraping for Demodex or fungal culture can help narrow things down. In ambiguous cases, a punch biopsy can reveal the psoriasiform pattern described above, which is fairly distinctive for dupilumab-associated head and neck dermatitis.

Treatment Options

A systematic review of facial and neck erythema associated with dupilumab found that the most commonly used treatments were topical corticosteroids, topical calcineurin inhibitors (like tacrolimus), and antifungal agents.¹³ The choice among these depends on what is thought to be driving the rash in a given patient.

Tacrolimus ointment: This is often the first-line topical because it calms inflammation without the skin-thinning effects of steroids, an important consideration for the face. A real-world study of patients using tacrolimus in combination with dupilumab found rapid improvement in facial dermatitis that tracked with overall eczema improvement, and no serious side effects.¹⁴
Antifungal therapy: When Malassezia overgrowth is suspected, oral or topical antifungals can be remarkably effective. In one case report, the oral antifungal itraconazole cleared dupilumab-associated facial redness, supporting the yeast-driven mechanism.⁸ Topical ketoconazole or ciclopirox can serve a similar role with fewer systemic concerns.
Roflumilast cream: This newer topical anti-inflammatory has shown promise as an add-on for residual disease in patients on dupilumab. In a retrospective chart review, clinician-documented improvement was reported in about 83% of patients who used roflumilast cream for areas that dupilumab alone did not fully clear.¹⁵ Patient-reported outcomes were somewhat more modest, and burning at the application site was noted in a small number of cases.
Anti-Demodex treatment: If mite overgrowth is identified through skin scraping, topical ivermectin or metronidazole (the same treatments used for rosacea) can be effective. Oral ivermectin is sometimes used for heavier infestations.

Most patients do not need to stop dupilumab to manage the facial rash. The pooled trial analysis found that no patients discontinued treatment because of facial rash events, and in clinical practice the rash is generally treated with add-on topicals while dupilumab continues to control the underlying eczema.³

When Switching Medications Makes Sense

For patients whose facial rash is severe, persistent despite topical treatments, or accompanied by significant eye problems, switching from dupilumab to a different biologic or an oral medication becomes worth discussing. A multicenter retrospective study compared outcomes in patients who switched to either tralokinumab (another biologic targeting IL-13 alone) or a JAK inhibitor. The results favored JAK inhibitors fairly clearly: facial redness resolved or improved in 85% of patients who switched to a JAK inhibitor, compared with 33% who switched to tralokinumab.¹⁶

The catch is that 57% of patients who switched eventually discontinued their new treatment after an average of about eight months, mostly because the new drug did not control their overall eczema as well as dupilumab had. This is the uncomfortable tradeoff that many patients face: dupilumab may be the most effective drug for their body eczema, but the one causing trouble on their face. JAK inhibitors resolve the facial issue but sometimes fall short on the bigger picture, and they come with their own monitoring requirements and side-effect profiles. These decisions are highly individual and are best made with a dermatologist who can weigh the severity of the facial rash against the overall disease control.

The Connection to Eye Problems

Dupilumab-associated facial redness does not exist in isolation. Many of the same patients also develop eye-related side effects, particularly conjunctivitis, blepharitis, and dry eye. These ocular issues share overlapping mechanisms with the facial rash: goblet cell loss in the conjunctiva, mucin deficiency, immune dysregulation, and Demodex proliferation around the eyelids all appear to play a role. Ocular side effects remain underrecognized and frequently underestimated in clinical practice. If you are experiencing both facial redness and eye irritation on dupilumab, it is worth flagging both to your dermatologist rather than treating them as unrelated complaints, because the underlying driver may be the same and the treatment strategy can sometimes address both.

Erythema Beyond the Face

While the face and neck get the most attention, dupilumab-associated redness can occasionally appear in other locations. Case reports have documented erythema on the hands and feet (acral erythema) developing after dupilumab injections. In these patients, the redness persisted even as their eczema lesions elsewhere improved, mimicking the pattern seen on the face.¹⁷ The underlying mechanism is thought to be similar, though the relative contributions of microbial shifts versus immune rebalancing may differ between body sites. These atypical presentations are rare, but they reinforce the idea that dupilumab can change the character of skin inflammation rather than simply suppressing it everywhere equally.

What Differs in Children

Dupilumab is now approved for children as young as six months with moderate-to-severe atopic dermatitis, which raises the question of whether the facial rash manifests differently in younger patients. A large pharmacovigilance analysis comparing adverse event profiles in children versus adults found that while many side effects overlap, certain reactions appear unique to each age group. The overall pattern of reported events differed between children and adults, with the median time to onset of any adverse event being notably shorter in children (reported as same day) compared with adults (about two weeks).

For facial redness specifically, pediatric dermatologists have noted that children may be harder to evaluate because the face is a common site for active eczema in young patients to begin with. Distinguishing between persistent eczema and dupilumab-induced erythema requires careful attention to whether the facial appearance changes character after starting treatment, particularly if it becomes more uniformly red and less patchy or scaly than the child’s previous facial eczema.

Living With It While It Lasts

For many patients, dupilumab-associated facial redness is a time-limited nuisance rather than a permanent feature. Some cases resolve spontaneously within the first several months of treatment as the skin’s microbial ecosystem re-equilibrates. Others require ongoing topical management but remain mild enough that patients choose to stay on dupilumab because the overall benefit to their eczema far outweighs the facial irritation. A smaller group has persistent, bothersome redness that eventually tips the decision toward switching medications.

Practical steps that dermatologists commonly recommend while you and your provider sort out the best approach include using a gentle, fragrance-free moisturizer on the face, avoiding topical steroids on facial skin unless specifically directed (since steroid history may be part of the problem), and incorporating a gentle antifungal wash such as ketoconazole shampoo used briefly on the face a few times per week. Keeping a photo diary of the rash can also help your clinician track whether it is improving, stable, or worsening, which guides treatment decisions more reliably than memory alone.